47
https://pubmed.ncbi.nlm.nih.gov/38116642
Daratumumab monotherapy shows acceptable safety and consistent efficacy in Indian patients with relapsed/refractory multiple myeloma.
https://pubmed.ncbi.nlm.nih.gov/38116642
Daratumumab monotherapy shows acceptable safety and consistent efficacy in Indian patients with relapsed/refractory multiple myeloma.